IL289100A - Egfr antigen binding fragments and compositions comprising same - Google Patents

Egfr antigen binding fragments and compositions comprising same

Info

Publication number
IL289100A
IL289100A IL289100A IL28910021A IL289100A IL 289100 A IL289100 A IL 289100A IL 289100 A IL289100 A IL 289100A IL 28910021 A IL28910021 A IL 28910021A IL 289100 A IL289100 A IL 289100A
Authority
IL
Israel
Prior art keywords
compositions
same
antigen binding
binding fragments
egfr antigen
Prior art date
Application number
IL289100A
Other languages
Hebrew (he)
Original Assignee
Amunix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amunix Pharmaceuticals Inc filed Critical Amunix Pharmaceuticals Inc
Publication of IL289100A publication Critical patent/IL289100A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL289100A 2019-06-26 2021-12-19 Egfr antigen binding fragments and compositions comprising same IL289100A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962866749P 2019-06-26 2019-06-26
US202063043486P 2020-06-24 2020-06-24
PCT/US2020/039682 WO2020264208A1 (en) 2019-06-26 2020-06-25 Egfr antigen binding fragments and compositions comprising same

Publications (1)

Publication Number Publication Date
IL289100A true IL289100A (en) 2022-02-01

Family

ID=74060335

Family Applications (1)

Application Number Title Priority Date Filing Date
IL289100A IL289100A (en) 2019-06-26 2021-12-19 Egfr antigen binding fragments and compositions comprising same

Country Status (12)

Country Link
US (1) US20230312729A1 (en)
EP (1) EP3990499A4 (en)
JP (1) JP2022538222A (en)
KR (1) KR20220038356A (en)
CN (1) CN114729056A (en)
AU (1) AU2020303586A1 (en)
CA (1) CA3143522A1 (en)
CL (1) CL2021003435A1 (en)
CO (1) CO2022000404A2 (en)
IL (1) IL289100A (en)
MX (1) MX2021015882A (en)
WO (1) WO2020264208A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240327538A1 (en) * 2023-02-10 2024-10-03 Amunix Pharmaceuticals, Inc. Compositions targeting prostate-specific membrane antigen and methods for making and using the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG193216A1 (en) * 2008-08-18 2013-09-30 Amgen Fremont Inc Antibodies to ccr2
AU2014206217B2 (en) * 2009-02-03 2015-09-17 Amunix Pharmaceuticals, Inc. Extended recombinant polypeptides and compositions comprising same
EP2729488A4 (en) * 2011-07-06 2015-01-14 Medimmune Llc Methods for making multimeric polypeptides
CA2852474A1 (en) * 2011-10-18 2013-04-25 Emory University Antibodies directed against influenza
CU24481B1 (en) * 2014-03-14 2020-03-04 Immutep Sas ANTIBODY MOLECULES THAT JOIN LAG-3
TWI744247B (en) * 2015-08-28 2021-11-01 美商亞穆尼克斯製藥公司 Chimeric polypeptide assembly and methods of making and using the same
CA3001362C (en) * 2015-10-30 2020-10-13 Genentech, Inc. Anti-htra1 antibodies and methods of use thereof
US11059908B2 (en) * 2016-09-29 2021-07-13 Amgen Inc. Low-viscosity antigen binding proteins and methods of making them
CN106632681B (en) * 2016-10-11 2017-11-14 北京东方百泰生物科技有限公司 Anti- EGFR and AntiCD3 McAb bispecific antibody and its application
CA3049791A1 (en) * 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
WO2019090355A1 (en) * 2017-11-06 2019-05-09 Children's National Medical Center Cells expressing antibodies and methods of treatment using the same

Also Published As

Publication number Publication date
JP2022538222A (en) 2022-09-01
CA3143522A1 (en) 2020-12-30
CN114729056A (en) 2022-07-08
US20230312729A1 (en) 2023-10-05
KR20220038356A (en) 2022-03-28
EP3990499A4 (en) 2023-07-05
CO2022000404A2 (en) 2022-05-31
EP3990499A1 (en) 2022-05-04
MX2021015882A (en) 2022-04-18
WO2020264208A1 (en) 2020-12-30
AU2020303586A1 (en) 2022-01-20
CL2021003435A1 (en) 2022-09-02

Similar Documents

Publication Publication Date Title
IL289102A (en) Cd3 antigen binding fragments and compositions comprising same
ZA202004494B (en) Anti-tmprss2 antibodies and antigen-binding fragments
EP3612218A4 (en) Trem2 antigen binding proteins and uses thereof
IL283754A (en) Anti-claudin antibodies, compositions comprising same and uses thereof
EP3928790A4 (en) Cd3 antigen binding fragment and application thereof
IL286717A (en) Immunotherapeutic compositions and use thereof
IL291246A (en) Anti-cd39 antibody compositions and methods
IL286690A (en) Anti-egfrviii antibodies and antigen-binding fragments thereof
IL285651A (en) Anti-trem2 antibodies, compositions comprising same and uses thereof
EP3847196A4 (en) Bispecific antigen binding proteins and uses thereof
GB201802338D0 (en) Antigen binding proteins
IL288727A (en) Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof
AU2020243430A1 (en) Antigen binding proteins
IL285813A (en) Antigen binding proteins that bind bcma
GB2596411B (en) Compositions and methods comprising IgA antibody constructs
IL289640A (en) Antibodies binding igc2 of igsf11 (vsig3) and uses thereof
IL277296A (en) Anti-pfrh5 antibodies and antigen-binding fragments thereof
IL291082A (en) Anti-vsig4 antibody or antigen binding fragment and uses thereof
IL289200A (en) Novel cancer antigens and methods
IL289100A (en) Egfr antigen binding fragments and compositions comprising same
IL291364A (en) Antigen binding proteins
IL308695A (en) Anti-nkg2a antibodies and compositions
IL290219A (en) Compositions and methods for binding antibodies and inhibiting neutralizing antibodies
EP3849561A4 (en) Compositions and methods for enhancing wound healing
GB201900687D0 (en) Immunotherapeutic methods and compositions